BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31350465)

  • 1. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations.
    Kumar N; Cramer GM; Dahaj SAZ; Sundaram B; Celli JP; Kulkarni RV
    Sci Rep; 2019 Jul; 9(1):10845. PubMed ID: 31350465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.
    Katsuno Y; Meyer DS; Zhang Z; Shokat KM; Akhurst RJ; Miyazono K; Derynck R
    Sci Signal; 2019 Feb; 12(570):. PubMed ID: 30808819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells.
    Skarkova V; Kralova V; Krbal L; Matouskova P; Soukup J; Rudolf E
    Exp Cell Res; 2018 Aug; 369(2):295-303. PubMed ID: 29842879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.
    Ramesh V; Brabletz T; Ceppi P
    Trends Cancer; 2020 Nov; 6(11):942-950. PubMed ID: 32680650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
    Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
    Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.
    Wen Q; Chen Z; Chen Z; Chen J; Wang R; Huang C; Yuan W
    Oncotarget; 2017 Jul; 8(29):47998-48011. PubMed ID: 28624791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
    Kurimoto R; Iwasawa S; Ebata T; Ishiwata T; Sekine I; Tada Y; Tatsumi K; Koide S; Iwama A; Takiguchi Y
    Int J Oncol; 2016 May; 48(5):1825-36. PubMed ID: 26984042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.
    Ruff M; Leyme A; Le Cann F; Bonnier D; Le Seyec J; Chesnel F; Fattet L; Rimokh R; Baffet G; Théret N
    PLoS One; 2015; 10(9):e0139179. PubMed ID: 26407179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.
    Druzhkova I; Ignatova N; Prodanets N; Kiselev N; Zhukov I; Shirmanova M; Zagainov V; Zagaynova E
    Clin Colorectal Cancer; 2019 Mar; 18(1):e74-e86. PubMed ID: 30415989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.
    Chen D; Huang J; Zhang K; Pan B; Chen J; De W; Wang R; Chen L
    Eur J Cancer; 2014 Nov; 50(17):3050-67. PubMed ID: 25310895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.
    Lin L; Li X; Pan C; Lin W; Shao R; Liu Y; Zhang J; Luo Y; Qian K; Shi M; Bin J; Liao Y; Liao W
    Cell Death Dis; 2019 Feb; 10(3):173. PubMed ID: 30787271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance.
    Lee JH; Kim SK; Khawar IA; Jeong SY; Chung S; Kuh HJ
    J Exp Clin Cancer Res; 2018 Jan; 37(1):4. PubMed ID: 29329547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
    Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
    Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
    Fortunato A
    Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.